Medinol v. Guidant patent trial
This article was originally published in The Gray Sheet
Executive Summary
July 10 trial date set for the U.S. District Court for the Southern District of New York to assess the validity of Medinol's '381 patent related to the flexibility of its coronary stents. If Medinol's claims hold, the jury will set damages based on Guidant's infringement of the Israeli firm's patent. Medinol was granted summary judgment on Feb. 10 that Guidant violated its patent (1"The Gray Sheet" March 6, 2006, p. 4). Once started, the trial is expected to conclude within seven trial days. The Israeli firm is asking for royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform...
You may also be interested in...
Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
Medinol is seeking royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform in an upcoming patent infringement trial that could begin by April
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.